Overview

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with genotype 1 chronic Hepatitis C Virus. All subjects will receive telaprevir (TVR) in combination with sofosbuvir (SOF) for 12 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

University of Florida

Collaborator:

Vertex Pharmaceuticals Incorporated

Treatments:

Sofosbuvir